Skip to main content

Vaginal Infection

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
TOL-463 Vaginal ovulePhase 11 trial
Active Trials
NCT01812889Completed26Est. May 2014
Bioperfectus
BioperfectusChina - Shanghai
1 program
Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram StainingN/A1 trial
Active Trials
NCT05997160Unknown5,590Est. Jun 2025
Carbon Biosciences
Carbon BiosciencesMA - Waltham
1 program
Vaginal swab for RT-PCRN/A1 trial
Active Trials
NCT05557318Unknown120Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsTOL-463 Vaginal ovule
BioperfectusResearch on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining
Carbon BiosciencesVaginal swab for RT-PCR

Clinical Trials (3)

Total enrollment: 5,736 patients across 3 trials

NCT01812889Allergy TherapeuticsTOL-463 Vaginal ovule

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

Start: Apr 2013Est. completion: May 201426 patients
Phase 1Completed
NCT05997160BioperfectusResearch on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining

Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining

Start: Sep 2023Est. completion: Jun 20255,590 patients
N/AUnknown
NCT05557318Carbon BiosciencesVaginal swab for RT-PCR

Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge

Start: Oct 2022Est. completion: Oct 2025120 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.